Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model

Title: Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
Authors: Carbognin L.; Simbolo M.; Calio A.; Vicentini C.; Delfino P.; Sperduti I.; Fassan M.; Schettini F.; Dieci M. V.; Griguolo G.; Pilotto S.; Fiorio E.; Arpino G.; Guarneri V.; De Placido S.; Conte P.; Manfrin E.; Brunelli M.; Scambia G.; Scarpa A.; Tortora G.; Bria E.
Contributors: Carbognin, L.; Simbolo, M.; Calio, A.; Vicentini, C.; Delfino, P.; Sperduti, I.; Fassan, M.; Schettini, F.; Dieci, M. V.; Griguolo, G.; Pilotto, S.; Fiorio, E.; Arpino, G.; Guarneri, V.; De Placido, S.; Conte, P.; Manfrin, E.; Brunelli, M.; Scambia, G.; Scarpa, A.; Tortora, G.; Bria, E.
Publisher Information: Churchill Livingstone
Publication Year: 2020
Collection: Padua Research Archive (IRIS - Università degli Studi di Padova)
Subject Terms: Breast cancer; CDK4; Lobular; Next-generation sequencing; Prognosi; Transcriptome analysis
Description: Introduction: The clinico-pathological and molecular factors that drive the prognosis of invasive lobular breast carcinoma (ILC) are not entirely explored. In this regard, the development and validation of a prognostic model for ILC and the investigation of the distribution of molecular abnormalities (focusing on CDK4/6 alterations) according to prognosis were the aims of this study. Patients and methods: Two clinico-pathological multi-center data-sets of early-stage ILC patients (Training/Validation Set, TS/VS) were gathered. A 3-class model was developed according to the multivariate analysis for disease-free-survival (DFS) and externally validated. Mutational, copy number variation and transcriptomic analyses by targeted next generation sequencing (NGS) were performed (and validated with quantitative PCR) in an explorative cohort of patients with poor and good prognosis. Results: Data from overall 773 patients (TS/VS: 491/282) were gathered. The developed model significantly discriminated low/intermediate/high risk in the TS (10-years DFS: 76.3%/67.6%/39.8%, respectively, p
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/32028173; info:eu-repo/semantics/altIdentifier/wos/WOS:000519815500008; volume:50; firstpage:56; lastpage:63; numberofpages:8; journal:THE BREAST; https://hdl.handle.net/11577/3327935
DOI: 10.1016/j.breast.2020.01.034
Availability: https://hdl.handle.net/11577/3327935; https://doi.org/10.1016/j.breast.2020.01.034; http://www.elsevier-international.com/journals/brst/
Rights: info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.36063C0B
Database: BASE